Gregory J Riely

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/170908/publications.pdf

Version: 2024-02-01

178 papers	53,160 citations	4388 86 h-index	4774 169 g-index
181 all docs	181 docs citations	181 times ranked	37844 citing authors

#	Article	IF	Citations
1	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. Journal of Thoracic Oncology, 2011, 6, 244-285.	1.1	4,127
2	Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung Cancer. New England Journal of Medicine, 2013, 368, 2385-2394.	27.0	3,181
3	Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain. PLoS Medicine, 2005, 2, e73.	8.4	3,022
4	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	21.4	2,702
5	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 2017, 23, 703-713.	30.7	2,473
6	Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers. Clinical Cancer Research, 2013, 19, 2240-2247.	7.0	2,097
7	Crizotinib in ROS1-Rearranged Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2014, 371, 1963-1971.	27.0	1,656
8	MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20932-20937.	7.1	1,557
9	Ceritinib inALK-Rearranged Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2014, 370, 1189-1197.	27.0	1,367
10	KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib. PLoS Medicine, 2005, 2, e17.	8.4	1,331
11	OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology, 2017, 2017, 1-16.	3.0	1,266
12	Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncology, The, 2012, 13, 1011-1019.	10.7	1,176
13	Molecular Determinants of Response to Antiâ€“Programmed Cell Death (PD)-1 and Antiâ€“Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Nonâ€“Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. Journal of Clinical Oncology, 2018, 36, 633-641.	1.6	1,109
14	Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptorâ€“Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors. Clinical Cancer Research, 2006, 12, 6494-6501.	7.0	783
15	Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 2872-2878.	1.6	747
16	Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 357-360.	1.6	735
17	Systemic Therapy for Locally Advanced and Metastatic Nonâ€“Small Cell Lung Cancer. JAMA - Journal of the American Medical Association, 2019, 322, 764.	7.4	720
18	Clinical Course of Patients with Nonâ€“Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib. Clinical Cancer Research, 2006, 12, 839-844.	7.0	688

#	Article	IF	Citations
19	Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncology, The, 2014, 15, 1119-1128.	10.7	631
20	Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations. Journal of Clinical Oncology, 2011, 29, 2046-2051.	1.6	616
21	Nonâ€“Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 740-801.	4.9	606
22	Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncology, The, 2018, 19, 1654-1667.	10.7	587
23	Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncology, The, 2016, 17, 234-242.	10.7	574
24	Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation. Clinical Cancer Research, 2011, 17, 1616-1622.	7.0	556
25	Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Nonâ€“Small-Cell Lung Cancer and Brain Metastases. Journal of Clinical Oncology, 2015, 33, 1881-1888.	1.6	555
26	Nonâ€“Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 497-530.	4.9	530
27	ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2013, 19, 4273-4281.	7.0	521
28	Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma. Clinical Cancer Research, 2008, 14, 5731-5734.	7.0	505
29	Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers. Clinical Cancer Research, 2012, 18, 6169-6177.	7.0	503
30	Systemic Therapy for Stage IV Nonâ€“Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2017, 35, 3484-3515.	1.6	492
31	Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer Discovery, 2017, 7, 596-609.	9.4	490
32	Acquired Resistance to KRAS^{G12C} Inhibition in Cancer. New England Journal of Medicine, 2021, 384, 2382-2393.	27.0	482
33	KRAS Mutations in Non-Small Cell Lung Cancer. Proceedings of the American Thoracic Society, 2009, 6, 201-205.	3.5	474
34	Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer. Science Translational Medicine, 2013, 5, 216ra177.	12.4	438
35	Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2127-33.	7.1	410
36	Targeting ALK: Precision Medicine Takes on Drug Resistance. Cancer Discovery, 2017, 7, 137-155.	9.4	405

#	Article	IF	Citations
37	Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design. Clinical Cancer Research, 2011, 17, 6298-6303.	7.0	383
38	Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Nonâ€“Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials. Clinical Cancer Research, 2009, 15, 5267-5273.	7.0	382
39	Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. Journal of Clinical Oncology, 2018, 36, 2532-2537.	1.6	381
40	Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncology, The, 2016, 17, 1653-1660.	10.7	365
41	Update onEpidermal Growth Factor ReceptorMutations in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2006, 12, 7232-7241.	7.0	357
42	Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2016, 17, 642-650.	10.7	352
43	Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitorâ€“Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations. Cancer Discovery, 2014, 4, 1036-1045.	9.4	348
44	Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses. Clinical Cancer Research, 2016, 22, 1103-1110.	7.0	326
45	Nonâ€“Small Cell Lung Cancer, Version 6.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 515-524.	4.9	323
46	Effects of Co-occurring Genomic Alterations on Outcomes in Patients withKRAS-Mutant Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 334-340.	7.0	323
47	Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 2013, 8, 346-351.	1.1	313
48	Nonâ€“Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1236-1271.	4.9	312
49	Therapy for Stage IV Nonâ€“Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. Journal of Clinical Oncology, 2020, 38, 1608-1632.	1.6	301
50	Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus. Clinical Cancer Research, 2007, 13, 5150-5155.	7.0	279
51	Adagrasib in Nonâ€“Small-Cell Lung Cancer Harboring a KRAS^{G12C} Mutation. New England Journal of Medicine, 2022, 387, 120-131.	27.0	269
52	Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma. Clinical Cancer Research, 2008, 14, 7519-7525.	7.0	267
53	Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers. Clinical Cancer Research, 2019, 25, 1063-1069.	7.0	257
54	Incidence of EGFR Exon 19 Deletions and L858R in Tumor Specimens From Men and Cigarette Smokers With Lung Adenocarcinomas. Journal of Clinical Oncology, 2011, 29, 2066-2070.	1.6	247

#	Article	IF	Citations
55	Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1â€“2 trial. Lancet Oncology, The, 2019, 20, 1691-1701.	10.7	233
56	Concurrent RB1 and TP53 Alterations Define aÂSubset of EGFR-Mutant Lung Cancers at risk forÂHistologic Transformation and Inferior Clinical Outcomes. Journal of Thoracic Oncology, 2019, 14, 1784-1793.	1.1	232
57	Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer. Clinical Cancer Research, 2020, 26, 2654-2663.	7.0	230
58	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell, 2022, 185, 563-575.e11.	28.9	223
59	Acquired Resistance ofEGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor. JAMA Oncology, 2015, 1, 982.	7.1	214
60	Use of Cigarette-Smoking History to Estimate the Likelihood of Mutations in Epidermal Growth Factor Receptor Gene Exons 19 and 21 in Lung Adenocarcinomas. Journal of Clinical Oncology, 2006, 24, 1700-1704.	1.6	202
61	Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. Clinical Cancer Research, 2018, 24, 3108-3118.	7.0	200
62	Therapy for Stage IV Nonâ€“Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. Journal of Clinical Oncology, 2021, 39, 1040-1091.	1.6	192
63	Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinomaâ€“Rationale for Comprehensive Mutation Profiling. Molecular Cancer Therapeutics, 2012, 11, 485-491.	4.1	191
64	Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature, 2021, 599, 679-683.	27.8	183
65	SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas. Journal of Thoracic Oncology, 2020, 15, 231-247.	1.1	172
66	Distinct Clinical Course of EGFR -Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib. Journal of Thoracic Oncology, 2012, 7, 1815-1822.	1.1	160
67	Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib. Cancer, 2015, 121, 3212-3220.	4.1	160
68	Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertionâ€“Positive Metastatic Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2021, 7, e214761.	7.1	160
69	Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib. Clinical Cancer Research, 2008, 14, 7060-7067.	7.0	156
70	Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Nonâ€“Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial. Cancer Discovery, 2021, 11, 1688-1699.	9.4	154
71	Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. Cancer, 2013, 119, 356-362.	4.1	143
72	A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer. Clinical Cancer Research, 2016, 22, 2351-2358.	7.0	141

#	Article	IF	Citations
73	Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RETâ€“Rearranged Lung Cancers. Journal of Thoracic Oncology, 2018, 13, 1595-1601.	1.1	137
74	Characteristics of Lung Cancers Harboring NRAS Mutations. Clinical Cancer Research, 2013, 19, 2584-2591.	7.0	134
75	The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer. Clinical Cancer Research, 2020, 26, 5701-5708.	7.0	133
76	A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations. Journal of Thoracic Oncology, 2011, 6, 1435-1437.	1.1	131
77	Associations Between Mutations and Histologic Patterns of Mucin in Lung Adenocarcinoma. American Journal of Surgical Pathology, 2014, 38, 1118-1127.	3.7	131
78	Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans. Journal of Thoracic Oncology, 2011, 6, 28-31.	1.1	126
79	Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib. Clinical Cancer Research, 2011, 17, 2521-2527.	7.0	116
80	Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. Clinical Lung Cancer, 2016, 17, e121-e129.	2.6	116
81	Packâ€years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer. Cancer, 2010, 116, 670-675.	4.1	111
82	Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers. Journal of Thoracic Oncology, 2014, 9, 1669-1674.	1.1	106
83	Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Journal of Clinical Oncology, 2015, 33, 1666-1673.	1.6	99
84	Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas. Journal of Thoracic Oncology, 2015, 10, 431-437.	1.1	98
85	A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. Journal of the National Cancer Institute, 2019, 111, 575-583.	6.3	96
86	Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers. JAMA Oncology, 2020, 6, 1048.	7.1	96
87	Erlotinib Versus Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Lung Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2014, 89, 322-329.	0.8	91
88	Thymomas and Thymic Carcinomas. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 562-576.	4.9	81
89	Therapeutic Strategies Utilized in the Setting of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. Clinical Cancer Research, 2014, 20, 5898-5907.	7.0	72
90	EGFR: The Paradigm of an Oncogene-Driven Lung Cancer. Clinical Cancer Research, 2015, 21, 2221-2226.	7.0	72

#	Article	IF	Citations
91	Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers. Journal of Thoracic Oncology, 2019, 14, 802-815.	1.1	71
92	Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach. Clinical Cancer Research, 2019, 25, 7113-7125.	7.0	69
93	Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, S146-S149.	1.1	66
94	Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12Câ€“Mutant Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 2209-2215.	7.0	65
95	Therapy for Stage IV Nonâ€“Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline. Journal of Clinical Oncology, 2022, 40, 3323-3343.	1.6	63
96	Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. Journal of Thoracic Oncology, 2018, 13, 1530-1538.	1.1	62
97	Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers. JCO Precision Oncology, 2018, 2, 1-12.	3.0	60
98	Therapy for Stage IV Nonâ€“Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline. Journal of Clinical Oncology, 2022, 40, 3310-3322.	1.6	60
99	Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements?. Lung Cancer, 2014, 86, 190-194.	2.0	57
100	A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy. Lung Cancer, 2007, 55, 181-185.	2.0	56
101	Randomized Phase II Study of Pulse Erlotinib Before or After Carboplatin and Paclitaxel in Current or Former Smokers With Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 264-270.	1.6	55
102	Driver mutations determine survival in smokers and neverâ€smokers with stage IIIB/IV lung adenocarcinomas. Cancer, 2012, 118, 5840-5847.	4.1	55
103	Massively Parallel Sequencing Identifies Recurrent Mutations in TP53 in Thymic Carcinoma Associated with Poor Prognosis. Journal of Thoracic Oncology, 2015, 10, 373-380.	1.1	54
104	Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors. PLoS ONE, 2017, 12, e0182665.	2.5	54
105	Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors. Journal of Thoracic Oncology, 2020, 15, 258-265.	1.1	53
106	A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma. JAMA Surgery, 2021, 156, e205601.	4.3	52
107	Frequency and outcomes of brain metastases in patients with HER2â€mutant lung cancers. Cancer, 2019, 125, 4380-4387.	4.1	51
108	Smarca4 Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung. Cancer Discovery, 2022, 12, 562-585.	9.4	48

#	Article	IF	Citations
109	Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. Lancet Respiratory Medicine,the, 2020, 8, 561-572.	10.7	47
110	YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E6030-E6038.	7.1	44
111	Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions. Clinical Cancer Research, 2021, 27, 2920-2927.	7.0	42
112	A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR -Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib. Journal of Thoracic Oncology, 2017, 12, 102-109.	1.1	40
113	Induction Therapy For Locally Advanced Thymoma. Journal of Thoracic Oncology, 2010, 5, S323-S326.	1.1	39
114	Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade. Cancer Discovery, 2021, 11, 59-67.	9.4	38
115	Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib. Lung Cancer, 2017, 108, 109-114.	2.0	36
116	MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions. Clinical Cancer Research, 2020, 26, 2932-2945.	7.0	35
117	Lungs Donâ€™t Forget: Comparison of the KRAS and EGFR Mutation Profile and Survival of Collegiate Smokers and Never Smokers with Advanced Lung Cancers. Journal of Thoracic Oncology, 2013, 8, 123-125.	1.1	33
118	Diagnosis and Treatment of Anaplastic Lymphoma Kinaseâ€“Positive Nonâ€“Small Cell Lung Cancer. Hematology/Oncology Clinics of North America, 2017, 31, 101-111.	2.2	32
119	Efficacy of Vemurafenib in Patients With Nonâ€“Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. JCO Precision Oncology, 2019, 3, 1-9.	3.0	31
120	Harnessing Clinical Sequencing Data for Survival Stratification of Patients With Metastatic Lung Adenocarcinomas. JCO Precision Oncology, 2019, 3, 1-9.	3.0	26
121	Twice weekly pulse and daily continuousâ€dose erlotinib as initial treatment for patients with epidermal growth factor receptorâ€“mutant lung cancers and brain metastases. Cancer, 2018, 124, 105-109.	4.1	25
122	Thymic Carcinoma Management Patterns among International Thymic Malignancy Interest Group (ITMIG) Physicians with Consensus from the Thymic Carcinoma Working Group. Journal of Thoracic Oncology, 2017, 12, 745-751.	1.1	23
123	Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers. Journal of Physical Education and Sports Management, 2019, 5, a003665.	1.2	23
124	KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic nonâ€“small cell lung cancer (NSCLC) harboring a KRAS^{G12C} mutation.. Journal of Clinical Oncology, 2022, 40, 9002-9002.	1.6	22
125	Clinical Application of Picodroplet Digital PCR Technology for Rapid Detection of EGFR T790M in Next-Generation Sequencing Libraries and DNA from Limited Tumor Samples. Journal of Molecular Diagnostics, 2016, 18, 903-911.	2.8	20
126	Renal cyst formation in patients treated with crizotinib for non-small cell lung cancerâ€”Incidence, radiological features and clinical characteristics. Lung Cancer, 2017, 106, 33-36.	2.0	20

#	Article	IF	Citations
127	KRAS G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma. Clinical Cancer Research, 2021, 27, 2604-2612.	7.0	20
128	Multimodality Therapy for Locally Advanced Thymomas: State of the Art or Investigational Therapy?. Annals of Thoracic Surgery, 2008, 85, 365-367.	1.3	19
129	The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations. Lung Cancer, 2008, 60, S19-S22.	2.0	18
130	Incorporation of Crizotinib into the NCCN Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 1328-1330.	4.9	18
131	The Impact of Cigarette Smoking on the Frequency of and Qualitative Differences inKRASMutations in Korean Patients with Lung Adenocarcinoma. Yonsei Medical Journal, 2013, 54, 865.	2.2	18
132	Long-term, disease-specific outcomes of thymic malignancies presenting with de novo pleural metastasis. Journal of Thoracic and Cardiovascular Surgery, 2020, 159, 705-714.e1.	0.8	18
133	Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. Lung Cancer, 2021, 159, 66-73.	2.0	17
134	KRAS mutational testing in the selection of patients for EGFR-targeted therapies. Seminars in Diagnostic Pathology, 2008, 25, 288-294.	1.5	16
135	Differences in the survival of patients with recurrent versus de novo metastatic KRASâ€mutant and EGFRâ€mutant lung adenocarcinomas. Cancer, 2015, 121, 2078-2082.	4.1	15
136	Radiogenomic evaluation of lung cancer â€" Are there imaging characteristics associated with lung adenocarcinomas harboring BRAF mutations?. Clinical Imaging, 2017, 42, 147-151.	1.5	14
137	CNS Metastases in Patients With MET Exon 14â€"Altered Lung Cancers and Outcomes With Crizotinib. JCO Precision Oncology, 2020, 4, 871-876.	3.0	14
138	Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC. JTO Clinical and Research Reports, 2022, 3, 100367.	1.1	13
139	CT Radiomic Features for Predicting Resectability and TNM Staging in Thymic Epithelial Tumors. Annals of Thoracic Surgery, 2022, 113, 957-965.	1.3	12
140	Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancers. Acta OncolÃ³gica, 2019, 58, 1634-1639.	1.8	10
141	Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor. JCO Precision Oncology, 2021, 5, 55-64.	3.0	10
142	Identification and Functional Characterization of EGFR V769M, a Novel Germline Variant Associated With Multiple Lung Adenocarcinomas. JCO Precision Oncology, 2017, 1, 1-10.	3.0	9
143	Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib. JCO Precision Oncology, 2021, 5, 695-700.	3.0	9
144	Encorafenib plus binimetinib in patients withBRAF^{V600}-mutant non-smallÂcell lung cancer: phase II PHAROS study design. Future Oncology, 2022, 18, 781-791.	2.4	9

#	Article	IF	Citations
145	Can IASLC/ATS/ERS subtype help predict response to chemotherapy in small biopsies of advanced lung adenocarcinoma?. European Respiratory Journal, 2014, 43, 1240-1242.	6.7	8
146	Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers. British Journal of Cancer, 2022, 126, 889-898.	6.4	8
147	Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: Is timing important?. Cancer Biology and Therapy, 2005, 4, 1096-1097.	3.4	6
148	A phase 1 study of osimertinib and bevacizumab as initial treatment for patients with EGFR-mutant lung cancers.. Journal of Clinical Oncology, 2017, 35, 9033-9033.	1.6	6
149	A Scalable Quality Assurance Process for Curating Oncology Electronic Health Records: The Project GENIE Biopharma Collaborative Approach. JCO Clinical Cancer Informatics, 2022, 6, e2100105.	2.1	5
150	Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic nonâ€“small cell lung cancer (mNSCLC): Treatment (tx) beyond progressive disease (PD) in platinum-pretreated patients (pts) with and without intracranial PD.. Journal of Clinical Oncology, 2022, 40, 9099-9099.	1.6	5
151	Chemo-immunotherapy outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer.. Journal of Clinical Oncology, 2021, 39, 9088-9088.	1.6	4
152	Automated NLP Extraction of Clinical Rationale for Treatment Discontinuation in Breast Cancer. JCO Clinical Cancer Informatics, 2021, 5, 550-560.	2.1	4
153	Comprehensive assessment of targetable alterations in lung adenocarcinoma samples with limited material using MSK-IMPACT, a clinical, hybrid capture-based, next-generation sequencing (NGS) assay.. Journal of Clinical Oncology, 2015, 33, e22160-e22160.	1.6	4
154	Nazartinib (EGF816) in patients with treatment-naÃ¯ve EGFR-mutant non-small cell lung cancer (NSCLC): Updated phase II results.. Journal of Clinical Oncology, 2020, 38, 9574-9574.	1.6	4
155	Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations. JTO Clinical and Research Reports, 2022, 3, 100256.	1.1	4
156	Validation of a Population-Based Data Source to Examine National Cancer Clinical Trial Participation. JAMA Network Open, 2022, 5, e223687.	5.9	4
157	Emerging Science and Therapies in Non-small-Cell Lung Cancer: Targeting the MET Pathway. Clinical Lung Cancer, 2014, 15, 475.	2.6	3
158	Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients. Journal of Oncology Practice, 2017, 13, 780-783.	2.5	3
159	Beyond â€œSecond-Lineâ€•in Nonâ€“Small Cell Lung Cancer: Therapy and Supportive Care. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e414-e418.	3.8	2
160	The Use of Antiangiogenic Agents for Lung Cancer in Elderly Patients: An Expert Panel Discussion Synopsis. Clinical Lung Cancer, 2017, 18, 255-258.	2.6	2
161	Clinical and genomic predictors of brain metastases (BM) in non-small cell lung cancer (NSCLC): An AACR Project GENIE analysis.. Journal of Clinical Oncology, 2021, 39, 2032-2032.	1.6	2
162	Clinical characteristics and anti-PD-(L)1 treatment outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer.. Journal of Clinical Oncology, 2020, 38, 9596-9596.	1.6	2

#	Article	IF	Citations
163	Lung cancer in 'Never-smokers': molecular factors trump risk factors. Oncology, 2010, 24, 38, 40.	0.5	2
164	Reply to M.C. Garassino et al. Journal of Clinical Oncology, 2011, 29, 3838-3839.	1.6	1
165	Improving therapy for patients with epidermal growth factor receptorâ€mutant lung cancer. Cancer, 2018, 124, 2272-2275.	4.1	1
166	Type A thymoma presenting with bone metastasis. Histopathology, 2018, 73, 701-703.	2.9	1
167	Pan-cancer evaluation of homologous repair deficiency somatic mutations and response to first-line anti-neoplastic therapy.. Journal of Clinical Oncology, 2021, 39, 10535-10535.	1.6	1
168	Translating inspiration from COVID-19 vaccine trials to innovations in clinical cancer research. Cancer Cell, 2021, 39, 897-899.	16.8	1
169	Multidisciplinary Management of Thymic Carcinoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 466-470.	3.8	1
170	Bronchioloalveolar Carcinoma of the Lung. , 2006, , 313-320.		0
171	Poly Adenosine Diphosphate-Ribose Polymerase Inhibitors and Heat Shock Protein 90 Inhibitors. Journal of Thoracic Oncology, 2011, 6, S1803-S1804.	1.1	0
172	The Use of Sunitinib as Maintenance Therapy in a Pediatric Patient With a Poorly Differentiated Thymic Carcinoma. Journal of Pediatric Hematology/Oncology, 2021, Publish Ahead of Print, .	0.6	0
173	Progression-free survival estimates in non-small cell lung cancer when RECIST is unavailable: Project GENIEâ€™s integration of genomic, therapeutic and phenomic data.. Journal of Clinical Oncology, 2020, 38, 9622-9622.	1.6	0
174	YES1 amplification as a primary driver of lung tumorigenesis and YES1/YAP1 amplifications as mediators of acquired resistance (AR) to ALK and EGFR tyrosine kinase inhibitors (TKIs).. Journal of Clinical Oncology, 2020, 38, e21591-e21591.	1.6	0
175	Identification of pretreatment genomic biomarkers and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers.. Journal of Clinical Oncology, 2022, 40, 9100-9100.	1.6	0
176	Outcomes of single-agent PD-(L)-1 versus combination with chemotherapy in patients with PD-L1-high (â‰¥ Tj ETQq0 0 0 rgBT /Overlo	1.6	0
177	Clinicopathologic and mutational landscape of BRAF^{V600E}-mutant nonâ€“small cell lung carcinoma.. Journal of Clinical Oncology, 2022, 40, 9084-9084.	1.6	0
178	Assessing effectiveness of first-line carboplatin, pemetrexed, and pembrolizumab in patients with recurrent/metastatic lung adenocarcinoma.. Journal of Clinical Oncology, 2022, 40, e21045-e21045.	1.6	0